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SUMMARY 
 
Introduction 
The aim of this study was to determine the types, frequency, distribution, and demographic 
characteristics of salivary gland tumours in a large representative sample. 
Patients and Methods 
We retrospectively analysed the medical records of 779 patients with tumours of the salivary glands 
surgically treated from 1985 and 2009 at a single institution. 
Results 
Of all cases, there were 500 benign and 279 malignant tumours. The average age of patients with 
benign and malignant salivary gland tumours was 50 and 56 years, respectively. No differences in 
age and incidence of tumours existed between males and females. The majority of the tumours 
occurred in the parotid gland (509), followed by the minor salivary glands (212), the submandibular 
gland (51) and lastly, the sublingual gland (7). Minor salivary gland tumours most frequently 
occurred on the palate, the pleomorphic adenoma being the most frequent benign tumour type and 
the adenoid cystic carcinoma being the most prevalent malignant tumour. Tumours of the 
sublingual gland were very rare, but all were malignant. Malignant tumours were more common in 
minor salivary glands and the submandibular gland. 
Conclusion 
This large study of salivary gland tumours in Croatia could improve our understanding of the 
significant differences in the global distribution of salivary gland tumours which have been 
reported. 
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INTRODUCTION 
 
"The usual tumour of the salivary gland is a tumour in which the benign variant is less benign than 
the usual benign tumour and the malignant tumour is less malignant than the usual malignant 
tumour.” (Ackerman and Del Regato, 1970). Salivary gland tumours are uncommon and constitute 2 
- 6.5% of all head and neck neoplasms (Auclair et al., 1991; Ellis and Auclair, 1996). As the 
incidence of these various tumours is low and their histologic classification is comparatively 
difficult because of the tumours’ morphologic heterogeneity, epidemiologic studies are often based 
on limited clinical numbers. Reports from several parts of the world have shown differences in the 
incidence of salivary gland tumours and variations in the frequency of each histologic type have 
also been reported (Eveson and Cawson, 1985; Spiro, 1986; Auclair et al., 1991; Wahlberg et al., 
2002; Poomsawat et al., 2004; Li et al., 2008; Subhashraj, 2008; Tian et al., 2010). 
The salivary glands are the site of origin of a wide variety of neoplasms. The histopathology of 
these tumours is said to be the most complex and diverse of any organ in the body (Subhashraj, 
2008). Unlike parotid and submandibular salivary gland tumours, the majority of tumours arising 
from the minor salivary glands are malignant (Spiro, 1986). Tumours arising from the sublingual 
gland are as a rule malignant (Speight and Barrett, 2002). 
Several studies exist involving large series of salivary gland tumours, but this is the first report on a 
large series of salivary gland tumours in Croatia. The present paper is a retrospective study 
representing 25 years of experience of salivary gland tumours from a single institution. The aim of 
this study was to determine the types, frequency, distribution, and demographic characteristics of 
salivary gland tumours in a large representative sample. 
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MATERIAL AND METHODS 
 
The medical records of patients with salivary gland tumours who were referred to the Department 
of Maxillofacial Surgery of the University Hospital Dubrava, the University of Zagreb, School of 
Medicine, were reviewed retrospectively. The period of review covered 25 years, from January 1, 
1985 to December 31, 2009. Patients with primary salivary gland tumours that underwent surgical 
treatment were included. The exclusion criteria were as follows: patients that did not undergo 
surgical treatment; patients with metastatic salivary gland tumours, patients who underwent surgical 
treatment with resection of the salivary gland due to extension of a primary skin cancer into the 
salivary gland, and patients who underwent resection of the salivary gland as part of an en bloc 
resection for oral or oropharyngeal carcinoma (Commando procedure). All cases were classified 
according to The World Health Organization's histologic typing of salivary gland tumours 
classification (Barnes et al., 2005). Furthermore, we have reviewed the histopathology of the 
tumours previously termed ''monomorphic adenoma'' and ''adenocarcinoma of nasal cavity'' and 
reclassified them according to the same WHO Classification. The clinical features, including age, 
gender, histologic type, and localisation of the tumours were obtained from clinical records. 
Nominal data were presented with absolute and relative frequencies and distributions were 
compared using a chi-square test. Numerical data were presented as the median value and data 
range, i.e., with minimal and maximal values, or when appropriate, using 5
th
 and 95
th
 percentiles, 
and compared using an ANOVA test with p<0.05 considered significant. 
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RESULTS 
 
During the 25-year period, 779 patients with salivary gland tumours underwent surgery (392 males 
[50.3%] and 387 females [49.7%]). The mean age of patients was 52 years (range, 1-93 years; 5
th
-
95
th
 percentile, 21-76 years). The age distribution is presented in Figure 1. The average age of 
patients with benign tumours was 50 years (5
th
-95
th
 percentile, 21-75 years) and for patients with 
malignant tumours, the average age was 56 years (5
th
-95
th 
 percentile, 21-80 years), a significant 
difference (F=7.6, p<0.001). There was no difference in age between males and females. 
The distribution of salivary gland tumours according to localisation and histology is presented in 
Table 1. The most common site was the parotid gland (509 cases [65.3%]), followed by the minor 
salivary glands (212 cases [27.2%]). There were 51 (6.6%) tumours of the submandibular gland and 
only 7 tumours of the sublingual gland (0.9%). Five hundred sixty-seven (72.8%) tumours occurred 
in the major salivary glands. 
Among tumours of the parotid gland, 5 accessory parotid gland tumours were included (2 
pleomorphic adenomas, and one of each of adenoid cystic carcinoma, high-grade mucoepidermoid 
carcinoma, and myoepithelioma). Accessory parotid tumours comprised 1% of overall parotid 
tumours (5/509) and had a malignancy rate of 40% (2/5). Two patients were female and three were 
male, and their ages ranged from 14 to 68 (mean 33 years). 
Of all cases, there were 500 (64.2%) benign and 279 (35.8%) malignant tumours. Two-thirds of 
parotid gland tumours were benign and the rest were malignant (383 vs. 126; Table 1). In the 
submandibular gland, there were 30 (58.8%) benign and 21 (41.2%) malignant tumours (Table 1). 
No benign tumours were found among the 7 sublingual gland tumours. 
The distribution of tumour histology is presented in Table 2. Among the benign tumours of the 
parotid gland, pleomorphic adenomas were predominant (66.8%), followed by Warthin's tumour 
(22.8%). Among malignant tumours of the parotid gland, 32.5% were mucoepidermoid carcinomas, 
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15.9% adenoid cystic carcinomas, 13.5% carcinoma ex-pleomorphic adenomas and 10.3% acinic 
cell carcinomas. 
Among the benign tumours of the submandibular gland, pleomorphic adenomas were predominant 
(93.4%). One case of sebaceous adenoma and one case of inverted ductal papilloma were found in 
the submandibular gland. Of the malignant tumours of the submandibular gland, adenoid cystic 
carcinoma was the most common histologic type (42.8%), followed by mucoepidermoid carcinoma 
(23.8%), carcinoma ex-pleomorphic adenoma (14.3%), and adenocarcinoma not otherwise 
specified, (9.5%). In the sublingual gland all tumours were malignant, 3 were mucoepidermoid 
carcinomas, 3 were adenoid cystic carcinomas, and one was carcinoma ex-pleomorphic adenoma. 
Of all minor salivary gland tumours, 87 (41.0%) were benign and 125 (59.0%) were malignant 
(Table 1). The distribution of 212 minor salivary gland tumours according to histological type and 
localisation is presented in Tables 2 and 3. The palate was the most frequent site (52.8%), followed 
by the maxillary sinus (17%), and the buccal mucosa (10.4%; Table 3). Of the benign tumours of 
the minor salivary gland, 96.7% were pleomorphic adenomas and among the malignant tumours, 
49.6% were adenoid cystic carcinomas, followed by mucoepidermoid carcinomas (14.4%), and 
carcinomas ex-pleomorphic adenomas (9.6%; Table 2). 
Tumour histology was dependent on anatomic localisation (Table 3). Benign tumours were frequent 
in the lip (64.3%), palate (53.6%), and the parapharynx (6 of 9), while malignant tumours were 
predominant in the maxillary sinus (97.2%), the rest being from rare sites (nasal cavity mucosa, 
upper and lower gingiva, tongue, ethmoid sinus and epipharynx). All 9 benign tumours of lips were 
pleomorphic adenomas, 7 of which were in the upper lip. Among the malignant tumours of the lips, 
4 of 5 were in the lower lip. The most frequent tumours of the palate were pleomorphic adenomas 
(53.6%) and adenoid cystic carcinomas (21.4%; Table 3). Adenoid cystic carcinoma was the most 
common minor salivary gland tumour of the maxillary sinus and pleomorphic adenoma was the 
most common tumour of the buccal mucosa, lip, and parapharynx. 
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DISCUSSION 
 
The salivary glands stand out as probably the tissue with the most diverse pathology in the human 
body. The WHO salivary gland tumour classification lists at least 38 subtypes of epithelial tumours 
alone, as well as several stromal types (Barnes et al., 2005).
 
Regardless of this diversity, salivary 
gland tumours are rare; and most of them occur in the major glands (75-91%), (Eveson and Cawson, 
1985). The literature to date reports that the site of the tumours is distributed mainly between the 
parotid gland (about 80%) and submandibular gland (20%), while very rarely are tumours found in 
the sublingual gland. Minor salivary gland tumours of the lips, oral cavity, pharynx, larynx, trachea, 
nasal mucosa, and paranasal sinuses are reported as uncommon (9-23%), (Eveson and Cawson, 
1985). Malignant tumours of the salivary glands are rare as compared to benign tumours and they 
are more frequent in the smaller glands. The most frequent malignant tumour of the parotid gland is 
mucoepidermoid carcinoma (30-50%), followed by adenoid cystic carcinoma (25%), carcinoma ex-
pleomorphic adenoma (15%), and acinic cell carcinoma (5%),
 
(Ito et al., 2005; Rapidis et al., 2007). 
This study reviewed 779 salivary gland tumours and showed a predominance of benign tumours 
(64.2%), similar to most published series (Batsakis, 1983; Eveson and Cawson, 1985; Wahlberg et 
al., 2002). Non-epithelial salivary gland tumours were very rare (Table 2). Also, this study 
demonstrated that the frequency of malignant tumours increases with age after the third decade and 
that the peak incidence of all patients with salivary gland tumours is in the sixth and seventh 
decades. Most studies have shown that salivary gland tumours are more common in females, but 
some studies have shown predominance in the male group and in the fourth decade of life 
(Jansisyanont et al., 2002; Vuhahula, 2004; Otoh et al., 2005; Ansari, 2007). We did not find such a 
discrepancy in the occurrence of tumours between females and males.  
Something which is not specifically addressed in table 2 are five accessory parotid gland tumours 
which are included among our results for parotid gland tumours. There were 2 pleomorphic 
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adenomas, 1 adenoid cystic carcinoma, 1 myoepithelioma, and 1 high-grade mucoepidermoid 
carcinoma. In general, 21-60% of people are estimated to have an accessory parotid gland which is 
normally not discovered unless a tumour is present, or as an incidental autopsy finding (Frommer, 
1977; Hamano et al., 2004). Though the accessory parotid gland itself is common, tumours of this 
small organ are rare (Klotz and Coniglio, 2000; Hamano et al., 2004). Accessory parotid tumours 
have been reported to occur in 1-7.7% of overall parotid tumours, with a malignancy rate of 35-
52%, though in some studies no malignancies have been reported (Kumar et al., 2003; Hamano et 
al., 2004; Wax et al., 2008). This incidence is comparatively larger than the standard expectation for 
malignancy in the parotid gland proper, which is 20-30%. This is in accordance with our findings of 
1% of parotid tumours being of accessory parotid gland origin, with a malignancy rate of 40%. A 
proper statistical analysis of accessory gland tumours is difficult because of their apparent low 
incidence. Klotz and Coniglio (2000) reported only four accessory parotid gland neoplasms over a 
six year period, all of which were benign pleomorphic adenomas. Lin et al. (2004) reported eight 
cases over a ten year period, three of which had malignant diseases.
 
In some studies, no cases were found in the sublingual gland confirming the low prevalence in this 
site (Ito et al., 2005; Spiro, 1986). Eveson and Cawson (1985) found a proportion of one case of 
sublingual tumour to 100 parotid tumours. In contrast, Satko et al. (2000) reported sublingual 
tumours in 33 out of 1,021 salivary gland tumours. In this study, tumours of the sublingual gland 
were found to be very rare, and none of them were benign in our patients. Malignant tumours were 
more common in the minor salivary glands and the submandibular glands than in the parotid gland. 
Eveson and Cawson (1985) showed that the frequency of malignant tumours increased with age 
after the third decade, was maximal in the eighth decade, and that malignant tumours were more 
common in the submandibular and minor salivary glands than in the parotid gland. Of 2410 
tumours, they found only seven tumours in the sublingual gland and six of these were malignant.
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In this study, an interesting result was that the average age of patients with benign and malignant 
tumours was 50 and 56 years, respectively. The difference was statistically significant (F=7.6, 
p<0.001). No difference in age and incidence rate was found between males and females. Some 
studies have reported that malignant tumours of the minor salivary glands are more common in 
males than females (Chaudhry et al., 1961; Van Heerden and Raubenheimer, 1991). However; other 
reports have indicated that this difference was not significant (Pires et al., 2007). In the literature, it 
has been reported that among submandibular gland tumours, 40% are malignant, the most frequent 
type being adenoid cystic carcinomas (40-50%), and followed by mucoepidermoid carcinomas (20-
25%), (Shaha et al., 1990; Ito et al., 2005; Preuss et al., 2007). Some authors have reported that 
mucoepidermoid carcinomas are the most frequent malignancy of the minor salivary glands, 
accounting for 10-15% of all salivary tumours (Locati et al., 2002; Triantafillidou et al., 2006). In 
this study, we found a different rate of occurrence of mucoepidermoid carcinoma depending on the 
localisation (i.e., 7.1% in the palate, 8.3% in the maxillary sinus, and 27.3% in the buccal mucosa). 
As expected, Warthin’s tumour was found in the parotid glands only. Similar findings are observed 
in most published series (Ito et al., 2005; Al-Khateeb and Ababneh, 2007). 
In the study by Spiro (1986), the parotid gland was the most frequent site, representing 70% of the 
cases, followed by the minor salivary glands and the submandibular gland with 22% and 8% of 
tumours, respectively.
 
All large series of salivary gland tumours showed similar results (Eveson and 
Cawson, 1985; Ellis and Auclair, 1996; Satko et al., 2000; Ito et al., 2005). In this study, among the 
minor salivary gland tumours, 125 (59.0%) were malignant. Some authors in large series of salivary 
gland tumours showed different results with the incidence of malignant tumours in minor salivary 
glands ranging from 45-49% (Eveson and Cawson, 1985; Auclair et al., 1991). As shown in Table 
3, the palate was the most common site for all minor salivary gland tumours, benign and malignant; 
about one-half of them (52.8%) were located in that region. The palate was followed by the 
maxillary sinus (17.0%), buccal mucosa (10.4%), lips (6.6%), and parapharynx (4.3%). All 9 
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benign tumours of the lips were pleomorphic adenomas and 7 were in the upper lip. Among the 
malignant tumours of the lips 4 of 5 were in the lower lip. The share of benign tumours of the lips is 
probably still higher, but some of the patients were operated as outpatients and histology for small 
surgical procedures is often not recorded in the tumour database. The remaining 19 cases were 
found in the nasal cavity mucosa, upper and lower gingiva, tongue, ethmoid sinus, and epipharynx, 
and all of those tumours were benign. The most frequent minor salivary gland malignant tumours 
were adenoid cystic carcinomas (62 cases [49.6 %]), followed by mucoepidermoid carcinomas (18 
[14.4 %]), and carcinomas ex-pleomorphic adenomas (12 [9.6%]). There were only four 
polymorphous low grade adenocarcinomas (PLGA) in a minor salivary gland, all in the palate, and 
no cases were identified in the major glands. Many authors suggested that PLGA is a relatively 
common minor salivary gland tumour (Ellis and Auclair, 1996;
 
Barnes et al., 2005). In this study, in 
minor salivary glands, adenoid cystic carcinoma was the most prevalent among all malignant 
tumours, as both these lesions are histological very similar, and based on the histological review 
performed by the authors. Pleomorphic adenoma was the most frequent tumour type in small 
salivary glands, with 84 cases, comprising 96.7 % of all benign minor salivary gland tumours of our 
series. The distribution of rare tumours of the minor salivary gland according to the histologic type 
and localisation is presented in Table 3. Li et al. (2008) concluded that most series reported in the 
literature included both major and minor salivary gland tumours, making it difficult to evaluate their 
actual frequency and site distribution.
 
Very few series have focused solely on intra-oral minor 
salivary gland tumours (Toida et al., 2005; Jaber, 2006; Pires et al., 2007; Bianchi et al., 2008). 
Pires et al. (2007) demonstrated that from a total of 546 minor salivary gland tumours, 55.9% were 
benign, that the two most common tumours were pleomorphic adenomas (33.2%) and 
mucoepidermoid carcinomas (22.9%), and the most commonly affected site was the palate (33.2%). 
Toida et al. (2005) in a retrospective study, suggested that the minor salivary gland tumours in 
Japan may be characterized by a higher incidence of benign tumours, especially of pleomorphic 
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adenomas, with a more marked tendency for female predominance, a higher incidence of palatal 
involvement, and a rarer occurrence of PLGA in comparison with those reported in the non-
Japanese studies. In the studies from outside of Japan, it has been reported that the most common 
malignant minor salivary gland tumours are adenoid cystic carcinomas and mucoepidermoid 
carcinomas. The incidence of adenoid cystic carcinomas and mucoepidermoid carcinomas has been 
reported to account for 7.7-48% and 6.5-41.3% of all tumours (11.5-51.1% and 16.7-73.6% of 
malignant tumours), respectively (Rivera-Bastidas et al., 1996; Lopes et al., 1999; Jansisyanont et 
al., 2002). In the largest series of intra-oral minor salivary gland tumours in 2007, Buchner et al. 
(2007) identified 380 tumours, of which 224 (59%) were benign and 156 (41%) were malignant. Of 
the benign tumours, pleomorphic adenomas were the most common (39.2%), and mucoepidermoid 
carcinomas were the most common malignant tumours (21.8%), followed by adenocarcinomas 
(7.1%) and adenoid cystic carcinomas (6.3%).
 
In accordance with the literature, in minor salivary 
gland tumours, the most common benign tumour was the pleomorphic adenoma, whereas the most 
common malignant tumour was either the mucoepidermoid carcinoma or adenoid cystic carcinoma 
(Eveson and Cawson, 1985; Auclair et al., 1991; Kokemueller et al., 2004; Poomsawat et al., 2004; 
Bianchi et al., 2008; Subhashraj, 2008; Tian et al., 2010). Comparing data from different studies, 
some discrepancies exist in the frequency and distribution of these tumours, which is possibly 
influenced by race and geographic location of the population in question. However, some reports in 
the literature are based on results from oral surgery institutions (predominantly minor salivary 
glands affected), while others are based on results from head and neck surgery (maxillofacial 
surgery/ENT) institutions, therefore it is expected that the distribution of tumours are not 
necessarily in concordance. Also, due to the extreme pathological diversity of salivary gland 
tumours, (and the presence of overlapping morphologies or changes in classifications – for 
example, PLGA were commonly classified as adenoid cystic carcinoma before 1991) interpretation 
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of results may depend greatly on pathologists' interpretations (Seifert and Sobin, 1992; Barnes et al., 
2005). 
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CONCLUSION 
 
Thus far, this is the largest study of primary salivary gland tumours in Croatia. The demographic 
data of salivary gland tumours presented herein can be helpful for a better understanding of both 
clinical and pathological characteristics of salivary gland tumours, including the geographic 
variations in the frequency and distribution of the disease in comparison with other similar 
published data. 
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FIGURES AND TABLES LEGENDS 
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Figure 1. Age distribution according to patients’ sex and tumour type 
 
 
Table 1. Benign and malignant salivary gland tumours according to the gland localisation, presented with number (N) and table percentages (χ
2
 
= 80.4, DF = 2, P < 0.001, calculated for parotid glands vs. minor salivary glands vs. both submandibular and sublingual glands as a third group) 
------------------------------------------------------------------------------------------------------------------------ 
    Benign tumours Malignant tumours  Total 
Localisation   N (%)   N (%)    N (%)  
------------------------------------------------------------------------------------------------------------------------ 
Parotid gland   383 (49.1)  126 (16.2)   509 (65.3) 
Minor salivary gland  87 (11.2)  125 (16.0)   212 (27.2) 
Submandibular gland  30 (3.9)   21 (2.7)   51 (6.6) 
Sublingual gland  0   7 (0.9)    7 (0.9) 
------------------------------------------------------------------------------------------------------------------------ 
Total    500 (64.2)  279 (35.8)   779 (100.0) 
------------------------------------------------------------------------------------------------------------------------ 
 
 
Table 2. Histological types of benign and malignant salivary gland tumours, presented with number (N) and column percentages
a 
---------------------------------------------------------------------------------------------------------------------------------------------------------- 
      Parotid gland  Minor glands  Submandibular gl. Sublingual gland  
Tumour type      N (%)   N (%)   N (%)   N (%) 
---------------------------------------------------------------------------------------------------------------------------------------------------------- 
Benign tumours 
Pleomorphic adenoma  256 (66.8)  84 (96.7)  28 (93.4)     
Warthin's tumour   87 (22.8)
b
          
 Myoepithelioma   9 (2.4)
c
  1 (1.1)       
Cystadenoma    7 (1.8)   1 (1.1)        
Basal cell adenoma   6 (1.6)          
 Sebaceous adenoma   5 (1.3)   1 (1.1)   1 (3.3)     
Oncocytoma    4 (1.0)          
Sebaceous lymphadenoma  3 (0.8) 
Haemangioma   3 (0.8)          
 Lymphangioma   2 (0.5)          
 Pseudotumour    1 (0.2)          
 Inverted ductal papilloma        1 (3.3)     
 
All benign tumours   383 (100.0)  87 (100.0)  30 (100.0)  0   
---------------------------------------------------------------------------------------------------------------------------------------------------------- 
Malignant tumours 
Mucoepidermoid carcinoma  41 (32.5)
d
  18 (14.4)
 d
  5 (23.8)
d
  3
d
 
Adenoid cystic carcinoma  20 (15.9)  62 (49.6)  9 (42.8)  3 
Ca ex-pleomorphic adenoma  17 (13.5)  12 (9.6)  3 (14.3)  1 
Acinic cell carcinoma  13 (10.3)  10 (8.0)  1 (4.8)     
Adenocarcinoma (NOS
*
)  6 (4.7)   9 (7.2)   2 (9.5)    
Basal cell adenocarcinoma  5 (3.9)          
Clear cell carcinoma   4 (3.2)   8 (6.4)       
Myoepithelial carcinoma  3 (2.4)      1 (4.8) 
Salivary duct carcinoma  3 (2.4)          
Lymphoepithelial carcinoma  3 (2.4)          
Squamous cell carcinoma  2 (1.6)          
Oncocytic carcinoma   2 (1.6)          
 2
Sebaceous carcinoma   2 (1.6)          
Malignant fibrous histiocytoma 2 (1.6) 
Haemangiopericytoma  1 (0.8)   2 (1.6)       
Rhabdomyosarcoma   1 (0.8) 
Synovial sarcoma   1 (0.8)       
PLGA
** 
       4 (3.2) 
 
All malignant tumours  126 (100.0)  125 (100.0)  21 (100.0)  7 
---------------------------------------------------------------------------------------------------------------------------------------------------------- 
Total      509   212    51   7 
---------------------------------------------------------------------------------------------------------------------------------------------------------- 
a
Percentages are presented only for columns with N>10 tumours. 
b
From those 8 were bilateral. 
c
From those 2 were bilateral. 
d
Out of 41 mucoepidermoid carcinomas in parotid gland, 13 were low-grade, 6 intermediate-grade and 22 high-grade. Out of 5 in submandibular 
gland, 2 were low-grade, 1 intermediate-grade and 2 high-grade. Out of 3 in sublingual gland, 1 was low-grade and 2 were high-grade.
 
Out of 18 
mucoepidermoid carcinomas in minor salivary glands, 2 were low-grade, 4 intermediate-grade and 12 high-grade. 
* 
Not otherwise specified 
** 
Polymorphous low-grade adenocarcinoma 
 
Table 3. Localisation and histological types of 212 minor salivary glands tumours, presented with number (N) and percentages
a
 
--------------------------------------------------------------------------------------------------------------------------------------------------------------- 
Localisation     Benign tumours Malignant tumours Total per localisation Total for all tumours 
Histological type   N (%)   N (%)   N (%)   (%) 
--------------------------------------------------------------------------------------------------------------------------------------------------------------- 
Palate 
 Pleomorphic adenoma  60 (53.6) 
Adenoid cystic carcinoma     24 (21.4) 
Mucoepidermoid carcinoma     8 (7.1) 
Ca ex-pleomorphic adenoma     7 (6.2) 
Acinic cell carcinoma     5 (4.5) 
PLGA        4 (3.6)  
Clear cell carcinoma      3 (2.7) 
Adenocarcinoma      1 (0.9) 
 All     60 (53.6)  52 (46.4)  112 (100.0)  (52.8) 
--------------------------------------------------------------------------------------------------------------------------------------------------------------- 
Maxillary sinus 
 Adenoid cystic carcinoma     22 (61.0) 
 Mucoepidermoid carcinoma     3 (8.3) 
Clear cell carcinoma      3 (8.3) 
Ca ex-pleomorphic adenoma     2 (5.6) 
Acinic cell carcinoma     2 (5.6) 
Adenocarcinoma      2 (5.6) 
Pleomorphic adenoma  1 (2.8) 
Haemangiopericytoma     1 (2.8) 
 All     1 (2.8)   35 (97.2)  36 (100.0)  (17.0) 
--------------------------------------------------------------------------------------------------------------------------------------------------------------- 
Buccal mucosa 
 Pleomorphic adenoma  9 (41.0) 
Cystadenoma    1 (4.5) 
Sebaceous adenoma    1 (4.5) 
Mucoepidermoid carcinoma     6 (27.3) 
Adenoid cystic carcinoma     4 (18.2) 
Acinic cell carcinoma     1 (4.5) 
 2
 All     11 (50.0)  11 (50.0)  22 (100.0)  (10.4) 
--------------------------------------------------------------------------------------------------------------------------------------------------------------- 
Lip 
 Pleomorphic adenoma  9 (64.3) 
Adenoid cystic carcinoma     2 (14.3) 
Clear cell carcinoma      2 (14.3) 
Adenocarcinoma      1 (7.1) 
 All     9 (64.3)  5 (35.7)  14 (100.0)  (6.6) 
--------------------------------------------------------------------------------------------------------------------------------------------------------------- 
Parapharynx 
 Pleomorphic adenoma  5 
Myoepithelioma   1 
Ca ex-pleomorphic adenoma     1 
Adenoid cystic carcinoma     1 
Haemangiopericytoma     1 
 All     6   3   9   (4.3) 
--------------------------------------------------------------------------------------------------------------------------------------------------------------- 
Nasal cavity mucosa 
Adenoid cystic carcinoma     4 
Adenocarcinoma      3 
 All        7   7   (3.3) 
--------------------------------------------------------------------------------------------------------------------------------------------------------------- 
Upper gingiva 
Acinic cell carcinoma     2 
Adenoid cystic carcinoma     1 
 Adenocarcinoma      1 
 All        4   4   (1.9) 
--------------------------------------------------------------------------------------------------------------------------------------------------------------- 
Lower gingiva 
 Ca ex-pleomorphic adenoma     2 
Mucoepidermoid carcinoma     1 
All        3   3   (1.4) 
--------------------------------------------------------------------------------------------------------------------------------------------------------------- 
 3
Tongue 
 Adenoid cystic carcinoma     2 
 All        2   2   (0.9) 
--------------------------------------------------------------------------------------------------------------------------------------------------------------- 
Ethmoid sinus 
 Adenoid cystic carcinoma     1 
Adenocarcinoma      1 
 All        2   2   (0.9) 
--------------------------------------------------------------------------------------------------------------------------------------------------------------- 
Epipharynx 
 Adenoid cystic carcinoma     1 
 All        1   1   (0.5) 
--------------------------------------------------------------------------------------------------------------------------------------------------------------- 
Total      87   125   212   (100.0) 
--------------------------------------------------------------------------------------------------------------------------------------------------------------- 
 
a
Percentages are presented only for localisation groups with N>10 tumours. 
